Nuvation Bio (Nuvation Bio) Short-Term Capital Lease Obligation : $1.97 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio Short-Term Capital Lease Obligation?

Nuvation Bio's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.97 Mil.

Nuvation Bio's quarterly Short-Term Capital Lease Obligation increased from Jun. 2023 ($1.28 Mil) to Sep. 2023 ($1.92 Mil) and increased from Sep. 2023 ($1.92 Mil) to Dec. 2023 ($1.97 Mil).

Nuvation Bio's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($0.86 Mil) to Dec. 2022 ($1.21 Mil) and increased from Dec. 2022 ($1.21 Mil) to Dec. 2023 ($1.97 Mil).

Nuvation Bio Short-Term Capital Lease Obligation Historical Data

The historical data trend for Nuvation Bio's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio Short-Term Capital Lease Obligation Chart

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

0.86

1.21

1.97

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Capital Lease Obligation	Get a 7-Day Free Trial											1.21	1.24	1.28	1.92	1.97

Nuvation Bio Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Nuvation Bio Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

NUVB:USA

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).